Ventoxen 100 Tablet | Pot

✔️ Precautions

• Tumor Lysis Syndrome (TLS): TLS has occurred early in therapy. Risk is highest in patients with bulky disease or reduced kidney function. Preemptive hydration, uric acid control, and frequent blood monitoring are essential.
• Neutropenia: Regular blood counts are required. Infections, including sepsis, may occur and need immediate management.
• Vaccinations: Avoid live vaccines during and after treatment until B-cell recovery.
• CYP3A Induction: Avoid strong/moderate inducers as they reduce drug effectiveness.

✔️ Dosage & Administration

Treatment starts with a low dose of 20 mg once daily for 7 days. The dose is gradually increased over 5 weeks to a maintenance dose of 400 mg daily to reduce tumor burden and lower the risk of tumor lysis syndrome (TLS).

With Rituximab: After completing the titration phase, continue with 400 mg of Ventoxen once daily. Begin Rituximab after 7 days of maintenance dosing. Ventoxen should be continued for 24 months starting from Day 1 of Rituximab treatment.

Monotherapy: After reaching 400 mg once daily, continue treatment until the disease progresses or the medication is no longer tolerated.

Elderly (65+ years): No dose adjustment needed.

Renal impairment: Mild to moderate cases do not need adjustment. Severe impairment or dialysis: safety not established; use only if the benefit outweighs the risk.

Hepatic impairment:

Mild to moderate: No adjustment needed.

Severe: Reduce dose by at least 50% and monitor closely.

Pediatrics: Safety and effectiveness not established for those under 18.

✔️ Interaction

• Strong CYP3A inhibitors (e.g., ketoconazole, ritonavir) can significantly raise Ventoxen levels and are contraindicated during initiation and dose escalation due to a heightened risk of TLS.
• Moderate CYP3A inhibitors (e.g., ciprofloxacin, fluconazole) should be avoided during the early treatment phase. If necessary, the Ventoxen dose should be halved, and patients must be closely monitored.
• After dose escalation, reduce the Ventoxen dose by 50% when taken with moderate CYP3A inhibitors and by 75% with strong ones.
• P-gp and BCRP inhibitors may also increase drug exposure; avoid their use during initiation and titration if possible.
• CYP3A inducers (e.g., rifampin, carbamazepine) can lower Ventoxen efficacy. These should be avoided.
• Foods to avoid: Grapefruit, Seville oranges, and starfruit due to CYP3A inhibition.

✔️ Contraindications

Allergy to Venetoclax or any of its components

Concomitant use with strong CYP3A inhibitors during titration

Use of St. John’s wort products

✔️ Adverse Reactions

Common side effects (≥20%): neutropenia, diarrhea, upper respiratory infections, nausea, anemia, fatigue

Serious adverse events (≥2%): pneumonia, febrile neutropenia, tumor lysis syndrome

✔️ Use in Pregnancy & Lactation

• Contraception: Women of reproductive age should use effective contraception during treatment and for 30 days afterward. Hormonal contraceptive effectiveness may be reduced; barrier methods are advised.
• Pregnancy: Not recommended due to potential fetal harm; animal studies show reproductive toxicity.
• Breastfeeding: Discontinue during treatment, as it's unknown if Venetoclax passes into breast milk.
• Fertility: May impact male fertility based on animal studies. Consider sperm preservation.

✔️ Storage:

Store below 30°C, protected from light and moisture. Keep out of children’s reach.